The glycan part of cellular glycoconjugates affords a versatile means to build biochemical signals. These oligosaccharides have an exceptional talent in this respect. They surpass any other class of biomolecule in coding capacity within an oligomer (code word). Four structural factors account for this property: the potential for variability of linkage points, anomeric position and ring size as well as the aptitude for branching (first and second dimensions of the sugar code). Specific intermolecular recognition is favoured by abundant potential for hydrogen/co-ordination bonds and for C-H/π-interactions. Fittingly, an array of protein folds has developed in evolution with the ability to select certain glycans from the natural diversity. The thermodynamics of this reaction profits from the occurrence of these ligands in only a few energetically favoured conformers, comparing favourably with highly flexible peptides (third dimension of the sugar code). Sequence, shape and local aspects of glycan presentation (e.g. multivalency) are key factors to regulate the avidity of lectin binding. At the level of cells, distinct glycan determinants, a result of enzymatic synthesis and dynamic remodelling, are being defined as biomarkers. Their presence gains a functional perspective by co-regulation of the cognate lectin as effector, for example in growth regulation. The way to tie sugar signal and lectin together is illustrated herein for two tumour model systems. In this sense, orchestration of glycan and lectin expression is an efficient means, with far-reaching relevance, to exploit the coding potential of oligosaccharides physiologically and medically.
Molecular basis for high-density coding
Biochemical signals can be compared with words which are formed by combinations of letters of an alphabet. The order of the letters (sequence) conveys information, and the theoretical number of sequence permutations is a measure of the coding capacity. The natural information storage by oligomer (word) formation primarily rests on three systems. When analysing the extent of coding capacity in the cases of nucleotides, amino acids and monosaccharides, the respective calculations result in enormous differences. It is in favour of sugar coding and attributable to structural features well-known as such, but, for this purpose, not yet generally appreciated [1] .
Phosphodiester and peptide bonds commonly lead to a linear structure defined completely by the sequence. Its permutations are the sole source of coding capacity. This situation is completely different for carbohydrates. There are four additional parameters in glycans underlying their superiority in coding capacity: (i) variability in linkage points (e.g. 1-2, 1-3, 1-4 or 1-6 for conjugation of L-fucose to glycans [2] ); (ii) variability in anomeric position (α or β; glycogen/starch in comparison with cellulose differ only in this parameter); (iii) variability in ring size (pyranose or furanose, with galactofuranose, e.g., present in microbial glycans); and (iv) introduction of branches (e.g. in common N-glycans, histo-blood group epitopes or the pentasaccharide of ganglioside G M1 shown in Figure 1 ). In summary, the structure of any disaccharide is only then characterized completely if the sequence and all listed parameters (first and second dimensions of the sugar code) are defined completely. Lactose is thus not simply galactose-glucose (Gal-Glc), but β-D-Galp-1,4-α-D-Glcp. Obviously, work to accomplish its structural elucidation is more demanding than for dinucleotides or dipeptides. This is the key factor to explain why breaking the sugar code has lagged behind deciphering the other two coding systems [1, 3] .
The four factors listed above generate a combinatorial diversity that sets carbohydrates widely apart from proteins or nucleic acids. In terms of coding capacity and given in absolute numbers, 6.4 × 10 7 hexapeptides are possible with 20 different letters, a quantity effectively dwarfed by the 1.44 × 10 15 theoretically possible hexasaccharides [4] . The site-specific occurrence of substituted monosaccharides, the equivalent of an 'umlaut' or other accent, e.g. by 6 -phosphorylation of mannose or N-and O-sulfation in glycosaminoglycans, increases further the pool of structures, written in the two dimensions of a branched glycan [1, 4] . A matching complexity on the level of the synthetic machinery, including dynamic aspects to ensure swift signal changes and a broad phylogenetic distribution with at least 41 modes to adorn a protein with a glycan part, facilitate the production of a large array of glycans in Nature [1, 2, [5] [6] [7] [8] . Summing up the salient message of these three paragraphs, particular structural features of carbohydrates enable high-density information storage. Combined with the eminent spatial accessibility of branch-end structures in glycoconjugates, it was prophetic to state in 1972 that glycans are "ideal for generating compact units with explicit informational properties" so that they can "impart a discrete recognitional role to the protein" [9] (see below for examples). The pentasaccharide chain of the ganglioside G M1 (each sugar unit is defined by its abbreviation) is not highly flexible in solution. Instead, it accesses only a few key-like shapes. A major source for the structural variability is the relative positioning of the Gal /Neu5Ac moieties, for which a dynamic equilibrium exists. Each existing conformer (shape) has its own bioactivity. The human lectin galectin-1 selects one distinct conformation (top) for binding [15] . A change concerning spatial presentation of the sialic acid in the branch, while maintaining the chain's structure, is required to allow the pentasaccharide to fit into the lectin site of the cholera toxin (bottom) (PDB code 2CHB/3CHB). The modulation of bioactivity by shape changes and the differential conformer selection epitomize level 3 in the compilation of modes of affinity regulation presented in Table 2 .
Towards this end, sugars are well suited for intermolecular recognition by their versatile engagement in hydrogen and co-ordination bonding, the latter preferentially with Ca 2+ , and C-H/π -interactions [1, 6, 10] . As a consequence, epimers can readily be distinguished by hydrogen bonding to a receptor which senses the spatial distribution of OH groups in the ligand [10] . At this stage, i.e. making contact with a receptor, the consideration of intramolecular flexibility also becomes an issue, and it comes up with a further advantageous attribute of glycans aiding information transfer.
Peptides, in general, are highly flexible (for access to files to view model peptides in motion, see [11] ). Consequently, a large entropic penalty is incurred by docking a peptide into a receptor site. Hereby, the attainable affinity is lowered. Introducing disulfide bridges (a telling example of a conserved four-disulfide core is given by the hevein or chitin-binding domain, the lectin site of a class of plant defence proteins and a number of animal toxins [1, 12] ) or embedding the relevant sequence part into a suitable context of a protein are efficient means to arrest the peptide in its bioactive conformation. In stark contrast, carbohydrates again offer a favourable feature for biorecognition: they often adopt only a few energetically privileged conformations (the third dimension of the sugar code) [10, 13] . The bulky rings connected by the glycosidic linkage tend to avoid all constellations with steric clashes. The resulting conformers can be likened to 'valleys' in a 'topographical' energy contour map or to key-like structures to fit into a 'lock' [13, 14] . Figure 1 shows two constellations of the pentasaccharide of ganglioside G M1 at its branch point, and, indeed, both conformers (shapes and keys) are bioactive. They target two separate 'locks', either a human protein (galectin-1) or a bacterial toxin [15] (for further details on functional implications, see below; for access to files to view dynamic mutual adaptation during a carbohydrate-protein contact, see [16] ). In this case, an arrested conformation at the α2-3 linkage will generate a ligand without cross-reactivity, a promising pharmaceutical perspective to exploit differential conformer selection. Also of note, an alteration in the linkage position engenders considerable consequences. A seemingly minor shift of the sialic acid from the 2-3 to a 2-6 linkage will cause a drastic increase in flexibility, with significant bearing on ligand properties, and also a sizeable shape change [17] . For the two in vivo receptors already mentioned, the interaction partners are frequently lectins. Lectins are set apart from carbohydrate-specific immunoglobulins, transport proteins for free saccharides and the enzymes involved in glycan synthesis and remodelling (for details on distribution, diversity, history and structures of lectins, see [1, 13, 18] ). The mentioned selection of a distinct conformer and then the cross-linking of ligands are the starting point for following biosignalling and the ensuing cellular responses [1, 19] .
Intuitively, the reader will expect the emergence of more than a few protein folds with lectin activity, if lectincarbohydrate recognition is biologically broadly relevant. Indeed, this is the case, as underscored by the compilation given in Table 1 , and, of course, intrafamily diversification abounds. Thus the development of a large variety of sites complementary to the shape(s) of carbohydrate determinants puts the cellular toolbox together to ensure translation of sugar signals into an array of biological responses. This process of a lectin-carbohydrate rendezvous is likely to be intimately regulated. Analysing this interaction closely discerns six levels of affinity regulation.
Levels of affinity regulation
The three dimensions of the sugar code already introduced embody the first three levels of affinity regulation. They are defined in Table 2 . In detail, we move from specificity to mono-and then oligo-saccharides, linear and with branches/substitutions (for examples which illustrate the effect of these features on glycan binding to two human lectins, see [20, 21] ), to the selection of conformers. As noted above, files of movies to view this interplay in a model system are accessible in [16] . As part of a natural glycan chain, these determinants are susceptible to the influence of the neighbouring groups. Regulatory events can now act on them, that is on the spatial presentation of their contact sites, e.g. in biantennary N-or O-glycans, taking us to the fourth level (Table 2) . Shifts in the conformational equilibrium are an intriguing way to reversibly modulate lectin-binding capacity. Molecular switches towards this end are, for instance, substitutions of N-glycans in their core, such as the introduction of α1-6 fucosylation or a bisecting GlcNAc moiety [1, 5, 6, 10] . Although they may have no contact with the lectin, they make their presence felt by affecting the entire glycan's shape [22] [23] [24] [25] . Thus they are molecular switches for the reactivity of the N-glycan. Another, equally important, topological factor is the clustering in multi-antennary glycans. In fact, the delineation of branching as a modulator of affinity, with respective N-acetylglucosaminyltransferases initiating a process which is under tight control [1, 5, 6] , means that adding new glycan Cluster effect with different glycoconjugates on the cell surface in spatial vicinity forming microdomains [32] antennae no longer appears to be random. Pioneering work on the relationship between the extent of N-glycan branching of serum glycoproteins and their uptake into hepatocytes via C-type lectins has revealed its physiological significance for clearance and has inspired continuous efforts in glycoengineering of pharmaglycoproteins to prolong survival using neoglycoproteins as tools [22] [23] [24] [25] [26] [27] [28] [29] . Altogether, the results exemplify the principle of complementary clustering for lectin sites and their ligands to reach an optimal fit. As summarized for level 4 in Table 2 , these spatial parameters are conspicuously relevant for lectin binding. Futhermore, these bulky glycan chains can surely also have a bearing on the functionality of the carrier protein and vice versa. The case of growth factor receptors and studies with animal/cell models engineered for loss/overexpression of a distinct glycosyltransferase teach important lessons in this respect [30] . Naturally, local clusters bringing separate glycan chains into spatial vicinity, e.g. in mucins [31] , or the formation of microdomains [32] will likewise lead to a high local density of binding partners suited for molecular interactions (levels 5 and 6 in Table 2 ). For this to occur, the strategic presentation of the ligand, e.g. on long-chain fatty acids in the case of a sulfatide letting the carbohydrate headgroup jut out of the membrane to make it a preferred target for galectin-4, and the grading of avidity of lectin binding to multivalent or clustered ligands with level of saturation, with exceptionally high values for the initial step, are major driving forces [33, 34] . Accessibility and multivalency thus combine with the suitable structure and shape of the ligand to modulate the affinity and therefore the propensity to be engaged in triggering biosignalling (Table 2) . Enzymatic remodelling of glycans or dynamic reorganization in the membrane due to its fluidity will then be parameters affecting the cell's responsiveness to a lectin.
With these sophisticated levels of affinity regulation defined, it is tempting to assume that suitable binding partners are present in situ (see above) and that their expression is also under appropriate control. Verification of these assumptions will let orchestration within the network of protein-carbohydrate interactions become plausible. In this sense, the detection of phenomenological markers on the level of glycans, e.g. associated with cell differentiation or malignancy [35, 36] , can then be perceived as a step to pinpoint functional determinants, by virtue of their interplay with an endogenous lectin. Two examples given below will illustrate how this emerging principle operates.
Glycans as functional markers
If glycans are biochemical signals on the cell surface, then their presentation, flanked by the presence of a lectin, will ordain the cells for a new fate. What is certain is that a tight regulation of the signal's presence will reduce the probability for 'misinterpretation'. Site-and stage-specific glycan remodelling in situ is a proper means towards this end. It can either consist of limited shortening of an available chain harbouring a masked (cryptic) contact site or an alteration of the glycomic profile based on expression of glycosyltransferases.
(i) Susceptibility for cell-density-dependent growth inhibition of neuroblastoma cells (SK-N-MC) in vitro rests on cellsurface presentation of a distinct carbohydrate signal. The performed remodelling is attributed to the activity of a cellsurface ganglioside sialidase. It turns gangliosides with several sialic acid moieties, such as G D1a/b into ganglioside G M1 (see Figure 1 for its pentasaccharide structure), the docking site for the homodimeric and therefore cross-linking galectin-1 [32, 37, 38] . The regulation of its cell-surface presentation coincides with the sialidase activity, ensuring matching quantities of the lectin for functional interplay with this glycan [37] . Its consequence is caspase-independent growth inhibition [38] . The same effect can be achieved by clinically known master regulators of gene expression, e.g. tumour suppressors.
(ii) Susceptibility to anoikis of pancreatic carcinoma cells (Capan-1) rests on the tumour suppressor p16
INK4a . Its expression is not only a switch for cyclin-dependent kinases. Beyond this activity, this tumour suppressor accounts for a reorganization of glycogene expression. It is shifted to facilitate increased production of galectin-1 ligands and, of functional significance, of the natural effector itself [39] . Lectin-glycan cross-linking on the cell surface, probably involving the α5β1 integrin, will then elicit signalling for the initiation of programmed cell death [39] . In essence, the context-associated glycosylation meets the criterion to ''impart a discrete recognitional role to the protein'' [9] , as quoted above.
Interestingly, the tumour suppressor p53 also induces up-regulation of a galectin. In detail, 14 of 7202 identified transcripts were found to be increased before the onset of p53-dependent apoptosis in colon carcinoma cells (DLD-1), prominently among them the mRNA for homodimeric galectin-7, hence described as p53-induced gene 1 [40] . It is also a potent effector for neuroblastoma growth inhibition in vitro [41] . Within this concept, the absence of the functional ligand in cell populations is predicted to make cells resistant to its growth regulator. Blocking sialidase activity in the neuroblastoma system mentioned does exactly that [37] . This situation is encountered, too, for CD7-negative leukaemic T-cells in Sézary syndrome, which are no longer susceptible to apoptosis induction by galectin-1 via CD7 binding [42] . Fittingly, progression of the disease is sustained by accumulation of this phenotype, exemplifying the clinical consequence of the negative selection process.
The emerging lesson from the co-regulation and intimate interplay between glycans and their cognate lectins is strengthened further by noting the equivalent capacity of other classes of oligosaccharides, e.g. Lewis compounds with/without sialylation or other ganglioside glycans (for structures, see [31, 32] ), to be homing devices towards endogenous lectins, in fact of different groups, e.g. Ctype lectins such as DC-SIGN (DC-specific intracellular adhesion molecule-3 grabbing non-integrin), collectins or selectins, I-type lectins, such as siglecs, and also the galectins mentioned, relevant in malignancy or inflammation (see Table 1 for folds) [43] [44] [45] . If then it becomes evident that these endogenous lectins are suitable probes to determine the reactivity of cells for these endogenous effectors, as for tumour cells before and after the natural cell-surface glycan remodelling [37] [38] [39] . The complementary side, i.e. lectins, can be mapped by neoglycoconjugates, presenting a custom-made carbohydrate ligand part [46] , or by lectinspecific antibodies. Having these reagents available makes tests on patient material feasible in order to figure out whether correlations between glycan-related parameters (presence and binding of lectins) and clinical features can be delineated. In this way, respective associations have already been noted, for instance in breast, head and neck, as well as urothelial, cancer [47] [48] [49] . Equally importantly, application of these tools is also gaining relevance for differential diagnosis in tumour pathology and in other medical areas such as accurate fibre typing in neuromuscular disorders [46, 50] . These clinical data, however, should not immediately be regarded as definitive proof for applicability of new therapeutic strategies. In fact, their availability can temper high expectations for a therapeutic perspective solely based on in vitro work, as recently seen in breast cancer [48] . Henceforward, the insights accrued into redirecting glycogene expression in a suppressorlike manner or applying target-specific (mini)lectins and glycoclusters to rationally manipulate lectin-mediated adhesion/growth regulation [1, 11, 13] will give research on glycans as emerging functional markers a clear direction.
